Summary

Next-generation sequencing—identifying new molecular targets in non–small cell lung cancer and subsets of patients who are responsive or resistant to novel compounds—will lead to patient-based therapy, the next step from current target-based treatment. The design of clinical trials is evolving to more efficiently test new compounds for new molecular targets and simultaneously develop predictive biomarkers.